产品
编 号：F506569
分子量：145360
分子量：145360
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 896723-44-7
产品详情
生物活性：
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer.
体外研究：
Farletuzumab (MORAb-003; 0-10 μg/mL; CHO-FR cells) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner.Farletuzumab (0.1-100 μg/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.Farletuzumab (0-10 μg/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway.
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer.
体外研究：
Farletuzumab (MORAb-003; 0-10 μg/mL; CHO-FR cells) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner.Farletuzumab (0.1-100 μg/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.Farletuzumab (0-10 μg/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备